GlassScriptPhysician profile
Jean S Bonnet
NPI 1164583787
$6,940.26
in general payments reported to CMS, 2019-2025
29 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $117 · 2021: $1,392 · 2022: $1,094 · 2023: $770 · 2024: $1,160 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,919.36 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $968.63 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $915.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $511.60 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $452.66 | 2021-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $308.72 | 2019-2021 | |
| Pfizer INC. | $300.32 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $248.45 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $234.33 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $188.88 | 2023-2025 | Rexulti, Jynarque, Abilify Maintena |
| Amarin Pharma, INC. | $186.85 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $100.66 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $80.75 | 2024-2025 | Ingrezza |
| Allergan, INC. | $66.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $63.90 | 2024 | Austedo Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.60 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $51.65 | 2022 | |
| Lundbeck LLC | $42.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.75 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $36.27 | 2022-2023 | Gvoke Hypopen |
| Cequr Corporation | $23.36 | 2025 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $21.78 | 2019 | |
| Global Blood Therapeutics, INC. | $21.21 | 2021 | |
| Sanofi Pasteur INC. | $21.06 | 2023 | |
| Shield Therapeutics INC | $17.39 | 2025 | |
| Lucid Diagnostics INC. | $16.10 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.03 | 2019 | |
| Abbvie INC. | $14.97 | 2025 | |
| Smith+Nephew, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Bonnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.